0001104659-23-023355.txt : 20230217 0001104659-23-023355.hdr.sgml : 20230217 20230217171732 ACCESSION NUMBER: 0001104659-23-023355 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20230214 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axcella Health Inc. CENTRAL INDEX KEY: 0001633070 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38901 FILM NUMBER: 23644057 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: THIRD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-868-0949 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: THIRD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Pronutria Biosciences, Inc. DATE OF NAME CHANGE: 20150206 8-K 1 tm237280d1_8k.htm FORM 8-K
0001633070 false 0001633070 2023-02-14 2023-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 14, 2023

 

 

AXCELLA HEALTH INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-38901   26-3321056
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

840 Memorial Drive
Cambridge, Massachusetts		 02139
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (857) 320-2200

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.001 Par Value   AXLA   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

 

 

 

Item 5.02            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 14, 2023, Axcella Health Inc. (the “Company”) entered into retention agreements (the “Retention Agreements”) with each of (i) William Hinshaw, President and Chief Executive Officer, (ii) Margaret Koziel, Senior Vice President, Chief Medical Officer and (iii) Paul Fehlner, Senior Vice President, Chief Legal Officer and Corporate Secretary to provide an incentive for their continued service with the Company subsequent to the restructuring event on December 14, 2022.

 

The Retention Agreements provide for retention bonuses of cash and equity in the event of certain Company actions as further described below. In connection with the retention bonuses provided under the Retention Agreements, each of Mr. Hinshaw, Dr. Koziel and Dr. Fehlner agreed to waive their rights to severance payments provided under their respective employment agreements in the event of a Terminations Without Cause or for Good Reason (as such terms are currently defined in their respective employment agreements).

 

The Company will pay $517,500 to Mr. Hinshaw in the event of (i) an affirmative decision by the Company’s Board of Directors (the “Board”) that the Company will cease to do business, (ii) Mr. Hinshaw’s Termination Without Cause or resignation for Good Reason (as such terms are currently defined in Mr. Hinshaw’s Employment Agreement, dated December 20, 2018) or (iii) the Board approving a sale of the Company or a corporate transaction that allows the Company to continue its operations, with fifty percent of the total retention payment payable on June 30, 2023 and the remainder payable on September 30, 2023.

 

The Company will pay $280,125 to Dr. Koziel in the event of (i) an affirmative decision by the Board that the Company will cease to do business, (ii) Dr. Koziel’s Termination Without Cause or resignation for Good Reason (as such terms are currently defined in Dr. Koziel’s Employment Agreement, dated December 1, 2021) and (iii) the Board approving a sale of the Company or a corporate transaction that allows the Company to continue its operations, with fifty percent of the total retention payment payable on June 30, 2023 and the remainder payable on September 30, 2023.

 

The Company will pay $270,123 to Dr. Fehlner in the event of (i) an affirmative decision by the Board that the Company will cease to do business, (ii) Dr. Fehlner’s Termination Without Cause or resignation for Good Reason (as such terms are currently defined in Dr. Fehlner’s Employment Agreement, dated December 19, 2018, as amended September 16, 2020) and (iii) the Board approving a sale of the Company or a corporate transaction that allows the Company to continue its operations, with fifty percent of the total retention payment payable on June 30, 2023 and the remainder payable on September 30, 2023.

 

In addition, the Company may, subject to Board review, offer a further equity incentive grant to each of Mr. Hinshaw, Dr. Koziel and Dr. Fehlner equal to 50% of such individual’s 2023 target annual bonus to continue employment with the Company in the event of a transaction referenced in (iii) above of an appropriate scale and that allows the Company to continue its operations indefinitely. Such equity incentive would vest fifty percent (50%) on the date six (6) months after grant, with the remaining fifty percent (50%) vesting on the date twelve (12) months after grant, provided that such individual remains employed by the Company on each vesting day.

 

The foregoing description of the Retention Agreements do not purport to be complete and is qualified in its entirety by reference to the text of the Retention Agreements, copies of which is attached to this Current Report on Form 8-K as Exhibits 10.1, 10.2 and 10.3 and incorporated herein by reference.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and William Hinshaw.
10.2   Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and Margaret Koziel.
10.3   Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and Paul Fehlner.
104   Cover page interactive data file (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AXCELLA HEALTH INC.
   
Date: February 17, 2023 By: /s/ William R. Hinshaw, Jr.
    William R. Hinshaw, Jr.
    Chief Executive Officer, President and Director

 

 

 

 EX-10.1 2 tm237280d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1 

 

Axcella Health Inc.
P.O. Box 1270
Littleton, MA 01460

 

Letter Agreement for Retention and to Amend Employment Agreement

 

February 14, 2023

 

Confidential

 

William Hinshaw

451 Marlborough Street

Unit 5

Boston, MA 02115

 

Dear Bill:

 

The purpose of this letter agreement (“Letter Agreement”) is to provide an incentive for you to continue employment with Axcella Health Inc. (“Axcella” or “the Company”)1 during the Transition Period (as defined below), and to amend the terms of your Employment Agreement with the Company dated December 20, 2018 that provide for severance in the event of a Termination Without Cause or resignation for Good Reason. All capitalized terms not defined in this Letter Agreement have the definitions set out in the Employment Agreement.

 

1.Retention Payment. In consideration for your agreement to this Letter Agreement, the Company will pay you a retention payment in the gross amount of five hundred seventeen thousand, five hundred dollars ($517,500) (“Retention Payment”) to be paid in the event of:

 

(i)an affirmative decision by the Board that the Company will cease to do business;

 

(ii)your Termination Without Cause or resignation for Good Reason (as such terms are currently defined in your Employment Agreement); or

 

(iii)the Company’s Board approving a Sale Event (i.e., a Change in Control as defined under your Employment Agreement) or a corporate transaction that allows the Company to continue its operations, with fifty percent of the total retention payment payable on June 30, 2023 and the remainder payable on September 30, 2023;

 

(the period from December 15, 2022 until whichever of (i), (ii), or (iii) occurs first constituting the “Transition Period”), in each case provided you remain employed by the Company during the Transition Period and subject to the conditions described in Section 4(b) of your Employment Agreement. The Company may make this Retention Payment in a lump sum (or in two payments in the case of event (iii)) as soon as reasonably practicable following the earliest of the above events. For the absence of doubt, this Retention Payment is guaranteed in exchange for your services during the Transition Period and so shall be considered wages and will be subject to withholdings.

 

2.Deal Incentive. In addition, the Company may, subject to Board review, offer a further equity incentive grant equal to 50% of your 2023 target annual bonus to continue employment with the Company in the event of a transaction referenced in (iii) above of an appropriate scale and that allows the Company to continue its operations indefinitely. Such equity incentive shall vest fifty percent (50%) on the date six (6) months after grant, with the remaining fifty percent (50%) vesting on the date twelve (12) months after grant, provided that you remain employed by the Company on each vesting day.

 

 

1 Whenever the term Axcella or the Company is used in this Agreement (including, without limitation, Section 6), it shall be deemed to include Axcella Health Inc. doing business as Axcella Therapeutics, and any and all of its divisions, affiliates, parents, subsidiaries, and any and all other related entities, and its directors, officers, employees, partners, members, representatives, trustees, agents, successors, predecessors, and assigns.

 

1

 

 

3.No Severance Pay or Benefits for Termination Without Cause or for Good Reason. You hereby waive any obligation of the Company to pay the Severance Amount or provide any contribution to health insurance costs under COBRA in the event of Termination Without Cause or for Good Reason as set out, respectively, in Sections 4(b)(i) and (ii) of the Employment Agreement.

 

4.During the Transition Period, the Company will continue to pay you your base salary, and you will continue to be eligible for a discretionary bonus.

 

5.No Modification of Any Other Terms. All other terms of the Employment Agreement are in full force and effect and are not otherwise modified by this Letter Agreement. For the absence of doubt, you will continue to be eligible for Change in Control benefits as provided in Section 5(a) of your Employment Agreement, in addition to the Retention Payment.

 

If you agree to the terms of this Agreement, please sign and return the enclosed copy of this Letter Agreement by no later than February 17, 2023.

 

Very truly yours,   Accepted and Agreed To:
     
/s/ Robert Rosiello   /s/ William Hinshaw
By: Robert Rosiello   William Hinshaw
Chairman of the Board    
     
Dated: February 14, 2023   Dated: February 14, 2023

 

2

 

 EX-10.2 3 tm237280d1_ex10-2.htm EXHIBIT 10.2

 

Exhibit 10.2

 

  Axcella Health Inc. P.O.
Box 1270
Littleton, MA 01460

 

Letter Agreement for Retention and to Amend Employment Agreement

 

February 14, 2023

 

Confidential

 

Margaret Koziel

198 Washington Avenue

Needham, MA 02492

 

Dear Margaret:

 

The purpose of this letter agreement (“Letter Agreement”) is to provide an incentive for you to continue employment with Axcella Health Inc. (“Axcella” or “the Company”)1 during the Transition Period (as defined below), and to amend the terms of your Employment Agreement with the Company dated December 1, 2021 that provide for severance in the event of a Termination Without Cause or for Good Reason. All capitalized terms not defined in this Letter Agreement have the definitions set out in the Employment Agreement.

 

1.Retention Payment. In consideration for your agreement to this Letter Agreement, the Company will pay you a retention payment in the gross amount of two hundred eighty thousand, one hundred twenty-five dollars ($280,125) (“Retention Payment”) to be paid in the event of:
   
(i)an affirmative decision by the Board that the Company will cease to do business;
   
(ii)your Termination Without Cause or resignation for Good Reason (as such terms are currently defined in your Employment Agreement); or
   
(iii)the Company’s Board approving a Sale Event (i.e., a Change in Control as defined under your Employment Agreement) or a corporate transaction that allows the Company to continue its operations, with fifty percent of the total retention payment payable on June 30, 2023 and the remainder payable on September 30, 2023;

 

(the period from December 15, 2022 until whichever of (i), (ii), or (iii) occurs first constituting the “Transition Period”), in each case provided you remain employed by the Company during the Transition Period and subject to the conditions described in Section 8 of the Restrictive Covenants Agreement attached as an Exhibit to and mentioned in Section 8 of your Employment Agreement. The Company may make this Retention Payment in a lump sum (or in two payments in the case of event (iii)) as soon as reasonably practicable following the earliest of the above events. For the absence of doubt, this Retention Payment is considered wages and will be subject to withholdings.

 

2.Deal Incentive. In addition, the Company may, subject to Board review, offer a further equity incentive grant equal to 50% of your 2023 target annual bonus to continue employment with the Company in the event of a transaction referenced in (iii) above of an appropriate scale and that allows the Company to continue its operations indefinitely. Such equity incentive shall vest fifty percent (50%) on the date six (6) months after grant, with the remaining fifty percent (50%) vesting on the date twelve (12) months after grant, provided that you remain employed by the Company on each vesting day.

 

 

1 Whenever the term Axcella or the Company is used in this Agreement (including, without limitation, Section 6), it shall be deemed to include Axcella Health Inc. doing business as Axcella Therapeutics, and any and all of its divisions, affiliates, parents, subsidiaries, and any and all other related entities, and its directors, officers, employees, partners, members, representatives, trustees, agents, successors, predecessors, and assigns.

 

1

 

 

3.No Severance Pay or Benefits for Termination Without Cause or for Good Reason. You hereby waive any obligation of the Company to pay the Severance Amount or provide any contribution to health insurance costs under COBRA in the event of Termination Without Cause or for Good Reason as set out, respectively, in Sections 5(a) and (b) of the Employment Agreement.

 

4.During the Transition Period, the Company will continue to pay you your base salary, and you will continue to be eligible for a discretionary bonus.

 

5.No Modification of Any Other Terms. All other terms of the Employment Agreement are in full force and effect and are not otherwise modified by this Letter Agreement. For the absence of doubt, you will continue to be eligible for Change in Control benefits as provided in Section 6(a) of your Employment Agreement, in addition to the Retention Payment.

 

If you agree to the terms of this Agreement, please sign and return the enclosed copy of this Letter Agreement by no later than February 17, 2023.

 

Very truly yours, Accepted and Agreed To:
 
/s/ William Hinshaw   /s/ Margaret Koziel
By: William Hinshaw   Margaret Koziel
President and Chief Executive Officer    
 
Dated: February 14, 2023   Dated: February 16, 2023

 

2

 

 EX-10.3 4 tm237280d1_ex10-3.htm EXHIBIT 10.3

 

Exhibit 10.3

 

Axcella Health Inc.
P.O. Box 1270
Littleton, MA 01460

 

Letter Agreement for Retention and to Amend Employment Agreement

 

February 14, 2023

 

Confidential

 

Paul Fehlner

125 Brookside Avenue

Ridgewood NJ 07450

 

Dear Paul:

 

The purpose of this letter agreement (“Letter Agreement”) is to provide an incentive for you to continue employment with Axcella Health Inc. (“Axcella” or “the Company”)1 during the Transition Period (as defined below), and to amend the terms of your Employment Agreement with the Company dated December 19, 2018 as amended September 16, 2020 that provide for severance in the event of a Termination Without Cause or for Good Reason. All capitalized terms not defined in this Letter Agreement have the definitions set out in the Employment Agreement.

 

1.Retention Payment. In consideration for your agreement to this Letter Agreement, the Company will pay you a retention payment in the gross amount of two hundred seventy thousand one hundred twenty-three dollars ($270,123) (“Retention Payment”) to be paid in the event of:
   
(i)an affirmative decision by the Board that the Company will cease to do business;
   
(ii)your Termination Without Cause or resignation for Good Reason (as such terms are currently defined in your Employment Agreement); or
   
(iii)the Company’s Board approving a Sale Event (i.e., a Change in Control as defined under your Employment Agreement) or a corporate transaction that allows the Company to continue its operations, with fifty percent of the total retention payment payable on June 30, 2023 and the remainder payable on September 30, 2023;

 

(the period from December 15, 2022 until whichever of (i), (ii), or (iii) occurs first constituting the “Transition Period”), in each case provided you remain employed by the Company during the Transition Period and subject to the conditions described in Section 4(b) of the Employment Agreement. The Company may make this Retention Payment in a lump sum (or in two payments in the case of event (iii)) as soon as reasonably practicable following the earliest of the above events. For the absence of doubt, this Retention Payment is considered wages and will be subject to withholdings.

 

2.Deal Incentive. In addition, the Company may, subject to Board review, offer a further equity incentive grant equal to 50% of your 2023 target annual bonus to continue employment with the Company in the event of a transaction referenced in (iii) above of an appropriate scale and that allows the Company to continue its operations indefinitely. Such equity incentive shall vest fifty percent (50%) on the date six (6) months after grant, with the remaining fifty percent (50%) vesting on the date twelve (12) months after grant, provided that you remain employed by the Company on each vesting day.

 

 

1 Whenever the term Axcella or the Company is used in this Agreement (including, without limitation, Section 6), it shall be deemed to include Axcella Health Inc. doing business as Axcella Therapeutics, and any and all of its divisions, affiliates, parents, subsidiaries, and any and all other related entities, and its directors, officers, employees, partners, members, representatives, trustees, agents, successors, predecessors, and assigns.

 

1

 

 

3.No Severance Pay or Benefits for Termination Without Cause or for Good Reason. You hereby waive any obligation of the Company to pay the Severance Amount or provide any contribution to health insurance costs under COBRA in the event of Termination Without Cause or for Good Reason as set out, respectively, in Sections 4(b)(i) and (ii) of the Employment Agreement.

 

4.During the Transition Period, the Company will continue to pay you your base salary, and you will continue to be eligible for a discretionary bonus.

 

5.No Modification of Any Other Terms. All other terms of the Employment Agreement are in full force and effect and are not otherwise modified by this Letter Agreement. For the absence of doubt, you will continue to be eligible for Change in Control benefits as provided in Section 5(a) of your Employment Agreement, in addition to the Retention Payment.

 

If you agree to the terms of this Agreement, please sign and return the enclosed copy of this Letter Agreement by no later than February 17, 2023.

 

Very truly yours,   Accepted and Agreed To:
     
/s/ William Hinshaw   /s/ Paul Fehlner
By: William Hinshaw   Paul Fehlner
President and Chief Executive Officer    
     
Dated: February 14, 2023   Dated: February 14, 2023

 

2

 

 EX-101.SCH 5 axla-20230214.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 axla-20230214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 axla-20230214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 tm237280d1_ex10-1img001.jpg GRAPHIC begin 644 tm237280d1_ex10-1img001.jpg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end GRAPHIC 9 tm237280d1img001.jpg GRAPHIC begin 644 tm237280d1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#VG5O$6G:' M=6<&H2F$76_9*1\H*[>I[?>^E:D7E#]/0^X_6O3IX'VM%5(/4\NIC_95W3FM#Z!HK MF_#?C72_$86*-_L][C)MY#R?7:?XOY^U2ZIXJL[$-';D7$XXPI^53[G_ KR M<3..&_C/E_K\3UL/%XG^#J;>:AJEWJM5RY4,/*I-WEIZ;G7T445[AXX4444 %%%% !1110 4444 %%%% !16=K MK%=$NBI((3J/J*==DC0)V!.?LK'/_ :T4+I/N[&,JO+*4;;*_P"?^1?HJKIA M)TFS).28$R3_ +HJU425FT:0ES14NX4444B@HHHH X?XD>&[_7;*TGL$$KVG MF%HL_,X;;]WU(V]*\J@T>7RC<7SBRM@2-\JG@RS#! Z?=ZX(YY'>O,]2LKZ6[,]^SRRRC<)6?>''JK= M"/IQ7OX!U/9J+T73N?.9BZ2J.2NWU[?U_5Q^D:LB:[9VNE1-:6AE4,2[ MM_[*,#Z]:;IWBEF_U/T.RVZY9MMZ2BL_[!_L MUM7P=#$)TZL;JWS^_>YRT,?5P[52E.SO\NFEMK'6Q6[7*I)9L+J*0X1X?FR? M0CJ#[$ UWGA?1[C2K>9KDJ'FVG8.=N,]3^->5:);:G:77VO3IFMO+^_,6VQ@ M>C9X/TYSZ5ZMX;U_^VEGC.UWMU3?*JE5H"\-FXL#&+@D ,_11GDUGQ^'E= UY?WD M\QZMYI5?P':K>IZB;!(DBB,US.VR*('&3W)/H*JBTUZ;YY-4AMB?^6<5N' _ M%JYZRIRJ6<7)KIT7XI7^_P"1VTG.,+J2BGUZO\&[?<076G7NE1FZTV\FDCC& MY[:=MP8#K@]JO&3^V=%6:UD>%Y%W(P;!5AV..V>*H7IUO3[29I9(;^WV$.0G MENHQUP..*L^%O^1O\ P.G_ #P5*5^=B=._4YI M%\/Q,H-Q>7/\ [/6M4RFX)*.FERX4HU92E/6S:796 MMT,.;3+^QQ+I=Y+)CK;W#;E;Z$]/\\U:U.]N+>VAC@11>7#!$!.0I[G\*TJQ M-=E:&\TR1(FE996(1>IXITY.I-*2O_7456"HTY.#:3M\M5MO_70='H)D4-?7 MUU/,>NV0JH^@IL^DWMH/,TN^ER.3#.VY6^F>G^>14G]L7?\ T![O]*/[8N_^ M@/=?I5WK7UMZ:6,FL+:RNGW]Z_WD5[>#4/"UEM/!TT4Z[9"I8KG.,MG%:5W_ ,B]/_UZM_Z!0TE91VYO\AQ< MFFY[\G^9)IF?['L\8S]G3&?]T5G0Z->WF9=5OYMS=(+=]B+_ (_YZU62_D>Q@^=45)-)66K]%MO^""7P^8E+Z??W4$PZ;I"RGZ@U:T>^FN[>2.Z4+= M6[F.7'0GU'UJLUKKUN-\6HP79'_+.6 )G\14?AR9[B?4Y98C%(TXW(3G:<N_HG8WJ***],\\\<^+/_ "-5K_UY M)_Z&]FJ8E*S6S'+6\HW(?<=U/N,&NJ^+/_(U6O_7DG_H;UE^&_ NJ M>("DQ7[+9'_EO(OWA_LCO_+WKZ:A*$<-%U-K?YGRU>$YXJ:IK6_^1U'AM])U M>[MY+*01W (9[64_.I[[3_$/<<^H%17L>EZ8'$C+O. M6+A[75OE_K^NYW3P-3V/NIN]GM;TZ'W* ME3G%*3LUY7ZW+6KWD%GID[S2*NZ-E4$\L<=!53PVRP^&;9W8*BJ[,QZ ;B:E MM_#^GP2^:T332]-\[%S^O%2)HMG'8O9(KK;L^\IO/Y?3BE3IU)5U4J62LUIJ M]TPJ3A&@Z=.[=[ZZ+9E?38VU&Z?5)U.PY2V1NR?WL>II+4_V3J9LFXL[@EK< MGHC=T_PK850JA5 "@8 ':H;NTAO8/)G4EU>E[5-M/9_AV_KU/+ M]@XQ3B_>6M^]]_D_PLNQFW$R6GB>*:=@D4MKY2NW3<&SC/TK9ZC(J&6UAGM_ M(G02ICH_.??ZUG_\(]:KQ#/=P+_=CF('ZT-PFE=V:T&HU:;?*DTW?>S_ ,B_ M=7EO90F6XE6-!Z]3]!WK-UB5$ETV])S;I+EG R &'!^E3P:%802B4QM-(.C3 M,7(_/BM%T61"CJ&4C!!&0:2E"#36H2A5J1:E9;6Z[.^NPB.DB!T964\AE.0: M))$B0O(ZH@ZLQP!68WA^R#%H&GMB>ODRE10OAZQWAIO.N".GG2%J.6E_,_N_ MX-A\]?;E7WZ?E<35KB*[\.7,T#AXV3@@>]377/AZ?'.;1L?]\5=,,9A,)C7R MBNW9CC'IBJMGI=K8[Q K!7&"K.6&/H::G%1MV=Q2I3171AV/(]CZ&HK32K6QG:6W5TW C;O)49. M>!^%03^']/FF,R(\$K=6@G5OS[G;AVO8JE5T:[:]$ MO+L:3R)$A>1U1%&2S' %8GA^XCNKK5)XCF-[C*GU&.M2CPW8E@T[7%S@Y FE M+"K4>CV<-^+R*,QR#^%&(4\8^[TZ5@XUYU(R:22\]=5;M8Z$Z,82BFVWY>=^ MY>HHHKM.0Q[WPSIFHZW'JM[!Y\T40BC23E%P2 GRAPHIC 10 tm237280d1_ex10-3im001.jpg GRAPHIC begin 644 tm237280d1_ex10-3im001.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2023
Entity File Number 001-38901
Entity Registrant Name AXCELLA HEALTH INC.
Entity Central Index Key 0001633070
Entity Tax Identification Number 26-3321056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 840 Memorial Drive
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 857
Local Phone Number 320-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol AXLA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 12 tm237280d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001633070 2023-02-14 2023-02-14 iso4217:USD shares iso4217:USD shares 0001633070 false 8-K 2023-02-14 AXCELLA HEALTH INC. DE 001-38901 26-3321056 840 Memorial Drive Cambridge MA 02139 857 320-2200 false false false false Common Stock, $0.001 Par Value AXLA NASDAQ true false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://axcellahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm237280d1_8k.htm axla-20230214.xsd axla-20230214_lab.xml axla-20230214_pre.xml tm237280d1_ex10-1.htm tm237280d1_ex10-2.htm tm237280d1_ex10-3.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm237280d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm237280d1_8k.htm" ] }, "labelLink": { "local": [ "axla-20230214_lab.xml" ] }, "presentationLink": { "local": [ "axla-20230214_pre.xml" ] }, "schema": { "local": [ "axla-20230214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "axla", "nsuri": "http://axcellahealth.com/20230214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm237280d1_8k.htm", "contextRef": "From2023-02-14to2023-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://axcellahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm237280d1_8k.htm", "contextRef": "From2023-02-14to2023-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001104659-23-023355-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-023355-xbrl.zip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end